Sports Ventures Acquisition Equity Warrant Exp 06 Jan 2028 *W EXP 01/06/2028
Change company Symbol lookup
Select an option...
AKICW Sports Ventures Acquisition Equity Warrant Exp 06 Jan 2028 *W EXP 01/06/2028
AZTA Azenta Inc
TSLX Sixth Street Specialty Lending Inc
PPG PPG Industries Inc
SP SP Plus Corp
RHCGF Ryman Healthcare Ltd
CSCO Cisco Systems Inc
UTZ UTZ Brands Inc
BSQR Bsquare Corp
APYX Apyx Medical Corp
Go

Company profile

Sports Ventures Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or other similar business combination. The Company may pursue acquisitions in any sector or industry. The Company intends to search for opportunities in the sports, media and entertainment sectors, including traditional and emerging sports as well as film and television production and infrastructure.

Price
Delayed
$0.0696
Day's Change
-0.0072 (-9.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0696
Day's Low
0.0696
Volume
(Light)

Today's volume of 100 shares is on pace to be much lighter than AKICW's 10-day average volume of 23,424 shares.

100

Regeneron shares up 1.4% premarket after earnings top estimates

6:47 am ET May 4, 2022 (MarketWatch)
Print

Regeneron Pharmaceuticals Inc. shares (REGN) rose 1.4% in premarket trade Wednesday, after the company beat consensus estimates for the first quarter. The company posted net income of $974 million, or $8.61 a share, for the quarter, down from $1.115 billion, or $10.09 a share, in the year-earlier period. Adjusted per-share earnings came to $11.49, ahead of the $9.68 FactSet consensus. Revenue rose 17% to $2.965 billion from $2.529 billion a year ago, also ahead of the $2.690 billion FactSet consensus. "We continued to see substantial U.S. sales growth for EYLEA and Dupixent worldwide," Chief Executive Leonard S. Schleifer said in a statement. "We are well-positioned to reach even more patients with type 2 inflammatory disease through FDA priority review designations for Dupixent in children with atopic dermatitis and in adults and adolescents with eosinophilic esophagitis." Regeneron is expecting the FDA to make a decision on data submitted for REGEN-COV, a treatment for COVID in in non-hospitalized patients and as prophylaxis in certain individuals, on July 13. Shares have gained 4.6% in the year to date, while the S&P 500 has fallen 12%.

-Ciara Linnane

	

(END) Dow Jones Newswires

May 04, 2022 06:47 ET (10:47 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.